12 results
6-K
EX-99.1
IMRN
Immuron Limited
28 Sep 23
Report of Foreign Private Issuer
8:43am
not be able to penetrate the potential market for a particular therapy, or indication, or gain market acceptance among health care providers, patients … and services. Uncertainty exists as to the reimbursement status of newly approved health care products and in foreign markets, including the U.S. If third
6-K
EX-99.1
IMRN
Immuron Limited
22 Jun 23
Report of Foreign Private Issuer
6:03am
Commission on Safety and Quality in Health Care:
https://www.safetyandquality.gov.au/publications-and-resources/resource-library/clostridium-difficile
6-K
EX-99.1
pbhjzbm8ive3c6ch97c
27 Jan 20
Report of Foreign Private Issuer
8:39pm
6-K
EX-1.1
ai6iajlk
19 Jul 19
Report of Foreign Private Issuer
6:07am
6-K
EX-1.1
3bk2875xnf89gxzwbf80
24 May 19
Immuron Prices Underwritten Public Offering of ADSs
1:03pm
20-F
ipo9ubhw1wehx5
2 Nov 17
Annual report (foreign)
12:00am
- Prev
- 1
- Next